OncoMatch/Clinical Trials/NCT07276789
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Is NCT07276789 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies LS301-IT 0.1 mg/kg for non small cell lung cancer (nsclc).
Treatment: LS301-IT 0.1 mg/kg — The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Kidney function
Patients with impaired renal function [excluded]
Liver function
Total bilirubin level ≤ 1.5 times upper limit; AST/SGOT and ALT/SGPT ≤ 2.5 times the upper limit of normal (ULN)
Cardiac function
History, or presence in the ECG at Screening, of any clinically significant abnormalities including cardiac conduction abnormalities [excluded]
Total bilirubin level >1.5 times upper limit; AST/SGOT and ALT/SGPT > 2.5 times the upper limit of normal (ULN); Patients with impaired renal function [excluded]; History, or presence in the ECG at Screening, of any clinically significant abnormalities including cardiac conduction abnormalities [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07276789 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages